No data to show
XSTO
QLIFE
Market cap2mUSD
, Last price
SEK
Name
Qlife Holding AB
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-62.25%
Revenues
89k
-63.52%
Net income
-56m
L-65.00%
CFO
-37m
L-10.59%
Earnings
Jun 26, 2025
Profile
Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo.Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. Its biomarkers include C-reactive protein home-testing capsule, PHE/Phenylalanine for PKU patients, and Sars-CoV-2/Influenza multiplex for virus/bacteria tests. The company was incorporated in 2019 and is based in Helsingborg, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 89 -63.52% | 244 -98.64% | 17,993 -54.58% | |||
Cost of revenue | 12 | 110,319 | (17,926) | |||
Unusual Expense (Income) | ||||||
NOPBT | 77 | (110,075) | 35,919 | |||
NOPBT Margin | 86.52% | 199.63% | ||||
Operating Taxes | (4,738) | (7,860) | ||||
Tax Rate | ||||||
NOPAT | 77 | (105,337) | 43,779 | |||
Net income | (55,981) -65.00% | (159,956) 71.74% | (93,141) 140.07% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 67,606 | 61,777 | 53,113 | |||
BB yield | -0.86% | -1,021,850.59% | -49,942.85% | |||
| Debt | ||||||
Debt current | 12,564 | 4,148 | ||||
Long-term debt | 8,699 | 13,875 | 97,722 | |||
Deferred revenue | ||||||
Other long-term liabilities | 2 | |||||
Net debt | 5,984 | 24,778 | 87,323 | |||
| Cash flow | ||||||
Cash from operating activities | (37,370) | (41,798) | (47,733) | |||
CAPEX | (8,689) | (594) | (42,940) | |||
Cash from investing activities | (16,803) | (20,840) | (42,940) | |||
Cash from financing activities | 55,228 | 48,997 | 32,726 | |||
FCF | (16,797) | (33,552) | 14,999 | |||
| Balance | ||||||
Cash | 2,715 | 1,661 | 14,547 | |||
Long term investments | ||||||
Excess cash | 2,711 | 1,649 | 13,647 | |||
Stockholders' equity | (317,677) | (253,395) | (134,013) | |||
Invested Capital | 324,947 | 250,517 | 277,605 | |||
ROIC | 0.03% | 16.94% | ||||
ROCE | 1.06% | 3,824.70% | 25.01% | |||
| EV | ||||||
Common stock shares outstanding | 3,911,218 | 304 | 53 | |||
Price | 2.02 10,050.75% | 0.02 -99.00% | 2.00 -94.01% | |||
Market cap | 7,900,660 130,684,361.74% | 6 -94.32% | 106 -92.94% | |||
EV | 7,906,644 | 24,784 | 87,429 | |||
EBITDA | 549 | (103,310) | 53,990 | |||
EV/EBITDA | 14,401.90 | 1.62 | ||||
Interest | 7,426 | 4,881 | ||||
Interest/NOPBT | 13.59% | |||||